Items tagged with Treatment
J&J can sell TB drug to minors after govt panel waives local trials (post)
New Delhi: A Government of India drugs advisory committee has approved the use of Johnson & Johnson’s (J&J) bedaquiline – used to treat tuberculosis (TB) – for minor patients in the country without conducting any local clinical trials first.
MPP sublicenses sutezolid, an investigational drug for TB treatment, paving the way for clinical development (post)
The Medicines Patent Pool (MPP) and the Bill & Melinda Gates Medical Research Institute signed an agreement to advance the development of investigational sutezolid-containing TB drug regimens, especially for low- and middle-income countries, where most people with TB live. The drug candidate sutezolid, in combination with other drugs, could potentially be used as an all-oral, shortened regimen for all forms of TB, including multidrug-resistant TB.
Patients in South Africa to access six-month, all-oral treatment for highly drug-resistant TB (post)
Pretoria, 10 December 2020 — TB Alliance welcomes the Wits Health Consortium and the South African National Department of Health (DoH)’s announcement of an initiative to provide a new, shorter treatment regimen for people affected with highly drug-resistant forms of tuberculosis (TB). Funded by the United States Agency for International Development, a new clinical access program (CAP) will enroll 400 people in South Africa for treatment with a three-drug, six-month, all-oral regimen of bedaquiline, pretomanid and linezolid (known as the BPaL regimen) that has been shown to demonstrate a favorable outcome in 90% of patients.1 This treatment was developed by TB Alliance and studied in its pivotal Nix-TB trial, which was also conducted in South Africa.
North Korea is about to exhaust its tuberculosis drug supply, experts warn (post)
North Korea has yet to report a single case of COVID-19—a remarkable success that, if true, the nation achieved after severing links with the outside world. But that isolation could soon exact a steep toll in other areas of public health: Humanitarian groups warn the isolated country is facing eroding food security, and they are bracing for a rapid spread of tuberculosis (TB), as supplies of first-line drugs against more treatable strains are expected to run out this month.
TB Alliance announces first patient dosed with TBAJ-587 in Phase 1 study (post)
NEW YORK (December 15, 2020)—TB Alliance announced that on December 1, 2020 the first dose was administered to a patient as part of a new Phase 1 study of its novel compound TBAJ-587 in healthy adult volunteers. New treatment options are urgently needed, especially as there is growing resistance to available drugs to treat tuberculosis (TB).
400 people in South Africa with highly drug-resistant TB to get new three-drug regimen (post)
Treatment of drug-resistant forms of tuberculosis (DR-TB) in South Africa has been transformed over the last decade. Most people with DR-TB no longer have to take daily injections and treatment is often completed in nine months, compared to 18 to 24 months in the past. Maybe most importantly, fewer people are dying of DR-TB and fewer people are suffering hearing loss, a common side effect of injections used in the past.
New TB drug regimen slashes treatment time (post)
Tuberculosis is an age-old respiratory scourge, with a new twist: growing resistance to multiple first- and second-line drugs. UF researchers and physicians report on using a novel treatment to slash treatment time — and cure — a patient with extensively drug-resistant TB.
Drug cocktail tested on extremely drug-resistant TB (post)
-- Tajikistan becomes the second country in the world to try out the BPaL regimen
-- WHO recommends the novel treatment under operational research conditions
-- New drug regimen is easy to use and more affordable
TB: New biomarker indicates individual treatment duration (post)
The treatment of tuberculosis (TB) is long, demanding, and expensive. In particular, the ever increasing emergence of resistant tuberculosis bacteria requires a lot of patience: In these cases, the WHO generally recommends a standard treatment duration of at least 18 months, as there are no reliable biomarkers for an early termination. Under the leadership of the DZIF scientists at the Research Center Borstel, six years of research have now succeeded in identifying a biomarker that points to an individual end of therapy based on the activity of 22 genes. In many cases, this probably allows the treatment to be shortened safely.
4-month TB regimen noninferior to 6-month regimen in people with HIV (post)
A 4-month daily regimen of rifapentine and moxifloxacin was noninferior to the standard 6-month regimen for tuberculosis treatment among people with HIV enrolled in a phase 3 clinical trial, researchers reported at CROI.
Page 55 of 106 · Total posts: 0
←First 54 55 56 Last→